Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metyrapone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 known ✓ | P15538 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metyrapone SCHEMBL30807826 | 1.00 | LMNA (0.81) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| Metyrapone SCHEMBL667561 | 1.00 | LMNA (0.81) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| Metyrapone SCHEMBL29917903 | 0.90 | TDP1 (1.00) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| Metyrapone SCHEMBL29462551 | 0.90 | TDP1 (1.00) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| Metyrapone SCHEMBL637432 | 0.90 | TDP1 (1.00) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| Metyrapone SCHEMBL5484012 | 0.88 | TDP1 (0.97) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL12260655 | 0.85 | CYP3A4 (0.84) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| Metyrapone SCHEMBL7020159 | 0.77 | LMNA (0.74) | LMNACYP1A2CYP3A4CYP11B1CYP11B2 | |
| Cadaverine Tartrate SCHEMBL27880305 | 0.77 | ALDH1A1 (0.60) | LMNACYP1A2CYP3A4TDP1KDM4E | |
| Cadaverine Tartrate SCHEMBL219351 | 0.77 | ALDH1A1 (0.78) | LMNACYP1A2CYP3A4TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068686-A1 | TREATMENT FOR BATTEN DISEASE | THE ROYAL VETERINARY COLLEGE (GB) | 2025-04-03 | — | — | WO | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-20180015172-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170216314-A1 | TOPICAL FORMULATIONS | NUVO RESEARCH INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9642912-B2 | Topical formulations for treating skin conditions | CRESCITA THERAPEUTICS INC. (CA) | 2017-05-09 | — | — | US | disclosed |
| WO-2016118787-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-9308181-B2 | Topical formulations, systems and methods | NUVO RESEARCH INC. (CA) | 2016-04-12 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | NUVO RESEARCH INC. (CA) | 2015-10-22 | — | — | US | disclosed |
| US-6267957-B1 | Attaching agents to tissue with transglutaminase and a transglutaminase substrate | PERICOR SCIENCE, INC. | 2001-07-31 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054998-A1 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999036570-A2 | TRANSGLUTAMINASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE INC (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | CYP11B1 587/4885LMNA 2554/4885CYP1A2 662/4885 |
| US-20150297723-A1 | TOPICAL FORMULATIONS FOR TREATING SKIN CONDITIONS | SMURF1, SGMS1, SMURF2 | CYP11B1 452/4885LMNA 2514/4885CYP1A2 2610/4885 |
| US-20170216314-A1 | TOPICAL FORMULATIONS | SMURF1, SGMS1, SPTLC1 | CYP11B1 1636/4885LMNA 2342/4885CYP1A2 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.